
A study on relapsed or refractory classic Hodgkin lymphoma (r/r CHL) reveals that a significant number of patients face treatment failure post high-dose chemotherapy and autologous stem-cell transplantation. Employing imaging mass cytometry, researchers analyzed 71 paired diagnostic and relapse biopsies, unveiling shared tumor microenvironment (TME) patterns in early relapse but divergence in late relapse. The study identified a distinct TME architecture involving CXCR5+ Hodgkin and Reed Sternberg cells and CXCL13+ macrophages. A prognostic assay, RHL4S, utilizing spatial parameters, effectively differentiated high and low-risk groups with validated outcomes in an independent r/r CHL cohort. The findings signify a breakthrough in spatial biomarker development for r/r CHL.
Like
Save
Share